GlaxoSmithKline halted its development program of SRT501, a special formulation of resveratrol which is reported to be the active ingredient from red wine, touted as an anti-ageing treatment. GSK obtained the right to develop the compound from Cambridge, Mass.-based Sirtris in 2008 with a $720 million package deal.
The experimental agent has been studied for several conditions, including Alzheimer’s disease, diabetes, obesity and cancer treatment and prevention.
In May the UK pharma giant said that a clinical trial of the compound in multiple myeloma patients was halted after kidney damages was found in some patients. The company noted that the particular formulation of Resveratrol ”may only offer minimal efficacy while having a potential to indirectly exacerbate a renal complication common in this patient population, and the company has no further plans to develop SRT501.